Faeth Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | — | — | — | — | — | — |
| SG&A Expense | — | $11.3M | $13.0M | $18.8M | $19.8M | $15.8M | $7.5M |
| Operating Income | — | $-22.3M | $-32.6M | $-37.1M | $-50.2M | $-37.5M | $-19.5M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | $32.0K | $90.0K | $144.0K | $219.0K | $670.0K | $1.7M |
| Pretax Income | — | $-21.1M | $-30.2M | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | — | — | — | — |
| Net Income | — | $-21.1M | $-30.2M | $-34.1M | $-48.6M | $-36.8M | $-20.1M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-16.72 | $-24.01 | $-1.22 | $-1.58 | $-1.33 | $-12.53 |
| EPS (Diluted) | — | $-16.72 | $-24.01 | $-1.22 | $-1.58 | $-1.33 | $-12.53 |
| Shares Outstanding (Basic) | 1.3M | 1.3M | 1.3M | 28.0M | 30.7M | 27.7M | 1.9M |
| Shares Outstanding (Diluted) | 1.3M | 1.3M | 1.3M | 28.0M | 30.7M | 27.7M | 1.9M |
| Dividends Per Share | — | — | — | — | — | — | — |